Ocrevus market seen topping $12 billion by 2030

The Business Research Company projects the global Ocrevus market will exceed $12 billion by 2030, with North America and the U.S. driving most demand. Growth is being lifted by rising multiple sclerosis diagnoses, broader access to biologics and the launch of a subcutaneous version of Roche’s drug.

Why it matters: - Ocrevus is becoming a larger piece of the multiple sclerosis treatment market as clinicians and health systems move toward therapies that are easier to administer and more accessible. - The report points to subcutaneous delivery as a key shift that could reduce treatment burden for patients and improve convenience for providers. - Ocrevus is forecast to exceed $12 billion in global sales by 2030, making it a major product within central nervous system drugs.

What happened: - The Business Research Company released its Ocrevus Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Oct. 28, 2026. - The report projects the Ocrevus market will grow at a 6% CAGR through 2030. - The global Ocrevus market is expected to top $12 billion by 2030. - The broader central nervous system drugs market is projected to reach about $225 billion by 2030. - The wider pharmaceuticals market is forecast to reach $2,496 billion by 2030. - F. Hoffmann-La Roche Ltd. holds 100% of the global Ocrevus market as of 2025, according to The Business Research Company.

The details: - North America is projected to be the largest regional market for Ocrevus by 2030 at $7.95 billion, up from $6.24 billion in 2025. - North America is forecast to grow at a 5% CAGR over that period. - The U.S. is expected to be the largest national market, reaching $7.87 billion by 2030 from $6.19 billion in 2025. - The U.S. is also forecast to grow at a 5% CAGR. - The report cites high multiple sclerosis prevalence, reimbursement support for biologics, broad access to specialized neurology centers and early diagnosis programs as demand drivers in North America. - In the U.S., demand is supported by physician preference for high-efficacy monoclonal antibodies, dedicated infusion networks, better patient awareness, improved diagnostics and regulatory support for neurological treatments. - Relapsing-remitting multiple sclerosis is expected to remain the largest disease segment in 2030, accounting for 73% of revenue, or roughly $9 billion. - The report says Ocrevus is segmented by formulation into liquid and tablet or capsule forms. - The report says administration routes are split between oral and injectable options. - End users include hospitals, retail pharmacies and online pharmacies. - Genentech launched Ocrevus Zunovo in September 2024 after FDA approval for relapsing and primary progressive MS. - Ocrevus Zunovo is the first subcutaneous version of the drug and can be given in 10 minutes, twice a year, using hyaluronidase-enabled delivery. - The report says RRMS and PPMS together will add more than $3 billion in market value by 2030, including about $2 billion from RRMS and around $1 billion from PPMS.

Between the lines: - The market outlook is being shaped less by one drug than by how MS care is changing around it: earlier diagnosis, broader biologic use and more convenient delivery. - Roche’s dominance means most of the market’s growth is likely to flow through one company’s product strategy, including lifecycle management and expanded access. - The subcutaneous launch could matter beyond convenience because it may help Ocrevus fit more easily into outpatient and specialty-care settings.

What's next: - The report expects continued growth through 2030 as MS diagnosis rates rise and reimbursement pathways widen. - Market competition is likely to focus on subcutaneous biologics, real-world evidence, broader indications and digital support tools. - Roche’s continued investment in MS innovation and market expansion will be central to how the category develops next. - The Business Research Company says its 2026 reports include market attractiveness scoring, TAM analysis, forecasting dashboards and future trend analysis.

The bottom line: - Ocrevus remains a highly concentrated market, but the combination of stronger MS demand and easier-to-use formulations is set to keep sales climbing.